MX344596B - Vacuna de subunidad recombinante del virus del dengue. - Google Patents

Vacuna de subunidad recombinante del virus del dengue.

Info

Publication number
MX344596B
MX344596B MX2013004741A MX2013004741A MX344596B MX 344596 B MX344596 B MX 344596B MX 2013004741 A MX2013004741 A MX 2013004741A MX 2013004741 A MX2013004741 A MX 2013004741A MX 344596 B MX344596 B MX 344596B
Authority
MX
Mexico
Prior art keywords
dengue virus
compositions
den4
present
virus vaccine
Prior art date
Application number
MX2013004741A
Other languages
English (en)
Other versions
MX2013004741A (es
Inventor
Beth-Ann Griswold Coller
Vidya B Pai
D Elliot Parks
Michele Yelmene
Andrew J Bett
Timothy Martyak
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2013004741A publication Critical patent/MX2013004741A/es
Publication of MX344596B publication Critical patent/MX344596B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición inmunogénica, caracterizada porque comprende una cantidad eficaz de monómeros de la proteína de envoltura ("E") del virus del dengue purificados de serotipo DEN-1, DEN-2, DEN-3 y DEN-4, un excipiente farmacéuticamente aceptable, y una cantidad eficaz de adyuvante; en donde cada proteína E constituye aproximadamente el 80% de la longitud de la proteína E de tipo silvestre empezando desde el residuo de aminoácido 1 en su extremo N, de tal manera que dicha proteína E es secretable al medio de crecimiento cuando se expresa de manera recombinante en una célula hospedera; en donde la cantidad de la proteína E DEN4es aproximadamente de 1.5 a aproximadamente 3 veces las cantidades individuales de las proteínas E DEN1, DEN2 Y DEN3; y en donde la composición induce la producción de anticuerpos neutralizantes en sujetos humanos.
MX2013004741A 2010-10-29 2011-10-27 Vacuna de subunidad recombinante del virus del dengue. MX344596B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40831010P 2010-10-29 2010-10-29
PCT/US2011/058026 WO2012154202A1 (en) 2010-10-29 2011-10-27 Recombinant subunit dengue virus vaccine

Publications (2)

Publication Number Publication Date
MX2013004741A MX2013004741A (es) 2013-06-05
MX344596B true MX344596B (es) 2016-12-20

Family

ID=47139466

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004741A MX344596B (es) 2010-10-29 2011-10-27 Vacuna de subunidad recombinante del virus del dengue.

Country Status (10)

Country Link
US (2) US9198964B2 (es)
EP (1) EP2632485A4 (es)
JP (1) JP6018575B2 (es)
KR (1) KR20130138789A (es)
AU (1) AU2011367817B2 (es)
BR (1) BR112013009649A2 (es)
MX (1) MX344596B (es)
MY (1) MY166534A (es)
SG (3) SG10201801947YA (es)
WO (1) WO2012154202A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10238734B2 (en) * 2010-03-23 2019-03-26 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
HRP20220796T1 (hr) 2010-10-01 2022-10-14 ModernaTX, Inc. Ribonukleinske kiseline koje sadrže n1-metil-pseudouracil i njihove uporabe
EP2632485A4 (en) 2010-10-29 2014-05-28 Merck Sharp & Dohme RECOMBINANT SUBUNIT VACCINE AGAINST DENGUE VIRUS
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (en) 2011-10-03 2020-03-04 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014204892A1 (en) * 2013-06-21 2014-12-24 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
GB201413086D0 (en) * 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods
CR20170280A (es) 2014-12-22 2017-08-21 Merck Sharp & Dohme Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
WO2018217906A1 (en) * 2017-05-23 2018-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus serotype 4 epitopes
MX2020005857A (es) 2017-12-07 2020-09-09 Merck Sharp & Dohme Formulaciones de composiciones de vacuna contra el virus del dengue.
WO2019124557A1 (ja) 2017-12-21 2019-06-27 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
MX2021001769A (es) * 2018-08-14 2021-04-19 Merck Sharp & Dohme Llc Un ensayo de neutralizacion de virus utilizando citometria de imagenes.
KR102301130B1 (ko) * 2018-12-27 2021-09-15 주식회사 이뮨메드 뎅기출혈열 진단 키트

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136561A (en) 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
CA2224724C (en) * 1995-05-24 2007-12-04 Hawaii Biotechnology Group, Inc. Subunit vaccine against flavivirus infection
JP2001511459A (ja) * 1997-07-31 2001-08-14 ハワイ バイオテクノロジー グループ， インコーポレイテッド フラビウイルス感染に対抗する組換え二量体エンベロープワクチン
US6416763B1 (en) 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
WO2004052293A2 (en) 2002-12-11 2004-06-24 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
AU2009240011A1 (en) 2008-04-22 2009-10-29 Cytos Biotechnology Ag Vaccine compositions for the treatment of dengue fever and uses thereof
EP2632485A4 (en) 2010-10-29 2014-05-28 Merck Sharp & Dohme RECOMBINANT SUBUNIT VACCINE AGAINST DENGUE VIRUS

Also Published As

Publication number Publication date
SG10201801947YA (en) 2018-04-27
SG10201508700XA (en) 2015-11-27
US20130216575A1 (en) 2013-08-22
EP2632485A4 (en) 2014-05-28
JP6018575B2 (ja) 2016-11-02
JP2013542224A (ja) 2013-11-21
WO2012154202A1 (en) 2012-11-15
US10137187B2 (en) 2018-11-27
EP2632485A1 (en) 2013-09-04
BR112013009649A2 (pt) 2016-07-12
AU2011367817A1 (en) 2013-04-18
US9198964B2 (en) 2015-12-01
AU2011367817B2 (en) 2015-05-28
MX2013004741A (es) 2013-06-05
SG189048A1 (en) 2013-05-31
MY166534A (en) 2018-07-10
CN103179983A (zh) 2013-06-26
US20160074502A1 (en) 2016-03-17
KR20130138789A (ko) 2013-12-19

Similar Documents

Publication Publication Date Title
MX344596B (es) Vacuna de subunidad recombinante del virus del dengue.
JP2013542224A5 (es)
PT2643345T (pt) Péptidos imunogénicos para utilizar na prevenção e/ou no tratamento de doenças infecciosas, doenças autoimunes, respostas imunitárias a alofatores, doenças alérgicas, tumores, rejeição de enxertos e respostas imunitárias contra vetores virais usados para a terapêutica de genes ou na vacinação genética
PH12018502403A1 (en) Hiv vaccine formulation
Egli et al. Vaccine adjuvants–understanding molecular mechanisms to improve vaccines
MX341775B (es) Vectores para vacunas y metodos para potenciar respuestas inmunes.
JP2016508999A5 (es)
RU2008114841A (ru) Фармацевтическая композиция, способная индуцировать защитный иммунный ответ против вируса денге, содержащая капсидный белок этого вируса
IL182440A0 (en) Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
EA201390617A1 (ru) Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики
Chen et al. Immunization with electroporation enhances the protective effect of a DNA vaccine candidate expressing prME antigen against dengue virus serotype 2 infection
RU2013147745A (ru) Фармацевтическая композиция для профилактики и(или) лечения заболеваний вич у людей
BR112013001946A2 (pt) vírus varicela zoster inativado, composição farmacêutica, método para preparar um vírus varicela zoster inativado, vacina, e, método para o tratamento de herpes zoster em um indivíduo
Follador et al. Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor
MX2016000107A (es) Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria.
MX2022010781A (es) Vacuna contra el virus sars-cov-2 con adyuvante cpg.
BR112017013270A2 (pt) ?composição de vacina contra vírus da dengue, métodos para induzir uma resposta imune contra dengue, para reduzir a probabilidade de infecção por dengue, ou prevenir ou atenuar os sintomas da mesma, e, uso de uma composição de vacina contra vírus da dengue?.
WO2012073257A3 (en) Vaccine formulation for prophylaxis and treatment of chandipura virus infections in mammals
WO2010141084A3 (en) Recombinant subunit west nile virus vaccine for protections of human subjects
EA033242B1 (ru) Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением
IL208862A (en) Use of a protein capable of eliciting an immune response against tat protein to prepare a drug for the prevention or treatment of AIDS (aids) in the patient and the preparations and vaccines associated with this use
PH12014502085A1 (en) Modified marek`s disease virus, and vaccines made therefrom
Dávila et al. Viral Control Induced by Therapeutic HIV Vaccine
TH142635A (th) วัคซีนไวรัสไข้เลือดออกหน่วยย่อยรีคอมบิแนนท์
Lisset et al. TETRA DIIIC: A NOVEL VACCINE CANDIDATE AGAINST DENGUE

Legal Events

Date Code Title Description
FG Grant or registration